Development of avian sarcoma and leukosis virus-based vector-packaging cell lines

Area of Science:

• * Molecular Virology
• * Retroviral Vector Development
• * Cancer Research

Background:

• * Avian leukosis virus (ALV) is a retrovirus with implications in cancer research.
• * Developing safe and efficient viral vectors requires removing viral replication elements.
• * Previous vector systems faced challenges with helper virus production and packaging efficiency.

Purpose of the Study:

• * To construct a replication-deficient ALV derivative (RAV-1 psi-) lacking essential cis-acting sequences.
• * To establish stable packaging cell lines expressing RAV-1 psi- for vector production.
• * To evaluate the packaging capacity and helper virus release of the developed system.

Main Methods:

• * Construction of a 5' deleted ALV derivative (RAV-1 psi-).
• * Stable expression of RAV-1 psi- in quail (QT6) and chicken embryo fibroblast cell lines.
• * Packaging of replication-defective v-src expression vectors using RAV-1 psi- expressing cell lines.
• * Quantitation of replication-defective viruses via immunocytochemistry.

Main Results:

• * RAV-1 psi- was stably expressed and replication-deficient in QT6 and chicken embryo fibroblast cells.
• * QT6-derived cell lines efficiently packaged four different replication-defective v-src vectors.
• * Helper virus release was very low or undetectable.
• * A sequence within gag, previously thought essential for packaging, was found unnecessary.

Conclusions:

• * The RAV-1 psi--expressing cell lines represent the first ALV-based vector-packaging system.
• * This system enables efficient packaging of replication-defective vectors with minimal helper virus.
• * The findings provide a valuable tool for avian retrovirus research and gene delivery.
• * Immunocytochemistry offers a sensitive alternative for characterizing replication-defective viruses.